A patient with chronic myeloid leukaemia was treated with interferon without using conventional cytotoxic agents. Bone marrow necrosis developed at the onset of blast transformation.
Case report A 58 year old caucasian man was referred for the investigation of dyspepsia. His spleen was palpable two finger breadths below the costal margin. Investigations showed a haemoglobin concentration of 13-4 g/dl, a white cell count of 58 x 1 09/l and a platelet count of 1697 x 109/L. The differential cell count showed 1% blasts, 5% promyelocytes, 15% myelocytes, 6% metamyelocytes, 66% neutrophils, 5% lymphocytes and 2% basophils. The 
Discussion
Interferon has recently been licensed for the treatment of chronic myeloid leukaemia. In this condition, interferon may achieve normalisation of the blood counts, regression of splenomegaly, and in a small proportion of patients a sustained loss of the Philadelphia chromsome.'°The response is slow and may take six months to achieve haematological remission, and cytogenetic changes may require 12 months' treatment. We elected to treat our patient solely with interferon and without prior cytoreductive chemotherapy because the presenting white cell count was not excessive.
The pathogenesis ofbone marrow necrosis is probably multifactorial and the complication may occur in a wide spectrum of diseases. It has been reported in chronic myeloid leukaemia during chronic phase and at blast transformation. As the marrow in chronic myeloid leukaemia is characteristically hypercellular, the rapid cell growth during clonal evolution to blast crisis could both infiltrate the vessel walls and compress the marrow blood supply, causing ischaemia of the marrow sinusoids.
Eleven cases of bone marrow necrosis and chronic myeloid leukaemia have been reported, but full documentation was not available for two reported by Brown,6 nor the three reported by Norgard et al. 9 Survival can be prolonged if necrosis occurs during stable chronic phase, as noted by Brown.6 Bain reported a 20 month survival from the onset of necrosis and subsequent development of myelofibrosis.7 Macheta et al described a survival of 12 months from necrosis in chronic phase. 8 Three patients survived less than four weeks when necrosis occurred at the time of disease progression.4 5 However, Scudla et al3 reported a 14 week survival following bone marrow necrosis at blast crisis. This patient recovered focal areas of normal haemopoesis after unspecified chemotherapy.
Our patient did not receive cytoreductive chemotherapy but was treated with interferon alone. Although this resulted in the normalisation of the peripheral blood and regression of splenomegaly, it did not prevent blast crisis and the subsequent development of bone marrow necrosis. We wonder, therefore, if despite the improvement in the peripheral blood the bone marrow remained hypercellular so that when blast transformation occurred, there was already a large residual cell mass in situ, thus increasing the risk of bone marrow necrosis by compression.
Interferon also has an inhibitory effect on bone marrow cells. The reduction in interferon and the subsequent abrupt withdrawal may have allowed rapid expansion of bone marrow cells.
Cytoreductive chemotherapy should be given before treatment with interferon for chronic myeloid leukaemia. There may also be a need to cover the withdrawal of interferon with conventional chemotherapeutic agents to prevent rapid bone marrow growth.
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